Aspire Biopharma Holdings (ASBP) Gross Margin (2025 - 2026)

Aspire Biopharma Holdings (ASBP) posted quarterly Gross Margin of 20.28% for Q1 2026, up 186.41% quarter-over-quarter from 23.47% in Q4 2025.

Aspire Biopharma Holdings (ASBP) Gross Margin (2025 - 2026) Analysis & Trends

Aspire Biopharma Holdings (ASBP) has reported Gross Margin for 2 consecutive years, with 20.28% the latest figure, recorded in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn	91.59%
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn	90.43%
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn	35.86%
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	76.90%
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn	63.27%
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	84.20%
9	Royalty Pharma	27.30 Bn	26.46 Bn	-	-
10	Aspire Biopharma Holdings	8.26 Mn	-3.91 Mn	-30,086.00	-47.68%

Download Data